Franklin Street Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Franklin Street Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,590	Closed	-$48K	–	165
2019 Q1	$48K	Hold	13,590	–	–	0.01%	155
2018 Q4	$54K	Buy	13,590 +660	+5%	+$8.44K	0.01%	142
2018 Q3	$255K	Buy	12,930 +10,400	+411%	+$263K	0.03%	137
2018 Q2	$80K	Sell	2,530 -80	-3%	-$2.88K	0.01%	155
2018 Q1	$97K	Buy	2,610 +28	+1%	+$1.84K	0.01%	157
2017 Q4	$204K	Buy	+2,582	New	+$191K	0.03%	155

Other funds holding MLNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Franklin Street Advisors's MLNT Position: Q2 2019 in Review

Franklin Street Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 13,590 shares — an estimated $48K sold.

Franklin Street Advisors first reported a position in MLNT in Q4 2017 and held it in 6 quarters. The position peaked at $255K in Q3 2018. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

Franklin Street Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Franklin Street Advisors sold 13,590 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $48K.
Franklin Street Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
Franklin Street Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $255K in Q3 2018.
53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Franklin Street Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.